Palatin Technologies stock analysis
Palatin Technologies (0KF3) Share Price & Analysis
0KF3 Stock Chart & Stats
- Day’s Range
- $6.00 - $6.00
- 52-Week Range
- $4.60 - $27.71
- Previous Close
- $6.73
- Volume
- N/A
- Average Volume (3M)
- 54
- Market Cap
- $12.22M
- Enterprise Value
- $35.04M
- Total Cash (Recent Filing)
- $7.49M
- Total Debt (Recent Filing)
- $223.68K
- Price to Earnings (P/E)
- ―
- Beta
- -0.57
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
MC4R Pipeline Potential
The MC4R pipeline shows differentiated preclinical potential through strong weight-loss activity, selectivity and potentially infrequent dosing. If these characteristics translate into human studies, they could support patient adherence, broader use in rare obesity disorders and meaningful long-term product differentiation.
Partnered Revenue Platform
Partnered assets are already generating collaboration and licensing revenue, reducing reliance on internally funded commercialization and validating external interest in the portfolio. Boehringer milestone rights, royalties and reimbursed research could provide additional non-dilutive support as development advances.
Improving Loss And Cash Use
The reduction in net loss and operating cash consumption indicates improved financial performance versus the prior year, partly supported by collaboration revenue. Although PTN is not self-funding, lower cash use can extend available resources and improve flexibility while clinical programs progress.
Bears Say
Going-Concern Funding Risk
PTN’s operating plans depend on securing additional capital because existing cash is insufficient for at least twelve months. This creates a durable execution risk: development timing may slip, financing may be dilutive, and unfavorable funding terms could weaken shareholder value.
Persistent Cash Burn And Losses
Persistent operating and free cash outflows show that PTN has not yet demonstrated a self-sustaining business model. Continued losses require recurring financing or partner support, limiting strategic flexibility and increasing the risk that valuable programs cannot be advanced at the planned pace.
MC4R Tolerability Risk
Nausea, vomiting and hyperpigmentation are established class challenges that could constrain adherence, labeling and commercial uptake of future MC4R therapies. These risks remain relevant through clinical development because long-term treatment requires a tolerable profile in chronically treated patients.
Palatin Technologies News
0KF3 FAQ
What was Palatin Technologies’s price range in the past 12 months?
What is Palatin Technologies’s market cap?
When is Palatin Technologies’s upcoming earnings report date?
How were Palatin Technologies’s earnings last quarter?
Is Palatin Technologies overvalued?
Does Palatin Technologies pay dividends?
What is Palatin Technologies’s EPS estimate?
How many shares outstanding does Palatin Technologies have?
What happened to Palatin Technologies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Palatin Technologies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carl Spana
- Employees
- 25
- Website
- palatin.com
- Address
- 301 Carnegie Center Drive, Princeton, NJ, 08540, US
Palatin Technologies (0KF3) Earnings & Revenues
0KF3 Earnings Call
Earnings Call SentimentNeutral
The call conveyed strong optimism about Palatin's technical progress, preclinical MC4R data, collaboration activity and planned clinical development. However, the positive outlook is materially offset by the explicit going-concern warning, the need for additional financing before development milestones can proceed, higher expected operating expenses and the prior toxicity issue in the oral program. Overall, the tone was cautiously optimistic but financially constrained.
View all GB:0KF3 earnings summaries0KF3 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 3 | 10 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 6 | 0 | 6 |














